Details der Publikation - Predictors and the optimal duration of sustained remission in rheumatoid arthritis

Predictors and the optimal duration of sustained remission in rheumatoid arthritis

Objective To determine predictors and optimal duration of sustained remission (SR) in patients with rheumatoid arthritis (RA). Methods A total of 428 consecutive patients with RA visiting our clinic routinely between 2012 and 2013 were evaluated. Seventy seven of these patients in DAS28 remission were enrolled and followed up for 62.2 ± 9.9 months. Patients in remission ≥ 6 months (SR) and shorter (non: N-SR) were compared in terms of demographic-clinical data and the psychosocial factors. At enrollment, 1st and 5th years, patients in DAS28, SDAI, and Boolean remission were determined. Results Sixty three patients were in SR and 14 in N-SR. Lower baseline DAS28 and HAQ scores, anti-CCP were positive predictors of SR. Although the presence of anxiety, depression, fibromyalgia, and fatigue were lower in the SR group, there was no significance. Patients in DAS28 remission (100%) at baseline reduced to 64% at 1st and 42.6% at 5th years. Patients satisfying SDAI and Boolean remission at these three visits were 49%, 44%, and 32.4% vs 41%, 28%, and 20.6%, respectively. If the duration of remission is defined as 6 months, the remission rates of SDAI at inclusion and fifth years’ visits were similar but Boolean remission rates differed significantly and if it is accepted as ≥ 12 months, both the SDAI and Boolean remission rates were not different. Conclusion Low DAS28 and HAQ scores at baseline, anti-CCP were positive predictors of SR. Instead of 6 months, remission duration for ≥ 12 months would probably help us to predict SR independently from the chosen criteria; Boolean or SDAI..

Medienart:	E-Artikel

Erscheinungsjahr:	2019
Erschienen:	2019

Enthalten in:	Zur Gesamtaufnahme - volume:38
Enthalten in:	Clinical rheumatology - 38(2019), 11 vom: 03. Juli, Seite 3033-3039

Sprache:	Englisch

Beteiligte Personen:	Yilmaz-Oner, Sibel [VerfasserIn] Gazel, Ummugulsum [VerfasserIn] Can, Meryem [VerfasserIn] Atagunduz, Pamir [VerfasserIn] Direskeneli, Haner [VerfasserIn] Inanc, Nevsun [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

BKL:	44.00$jMedizin: Allgemeines 44.83$jRheumatologie$jOrthopädie
Themen:	ACR/EULAR definition of remission Disease activity score Predictors Rheumatoid arthritis SDAI Sustained remission

Anmerkungen:	© International League of Associations for Rheumatology (ILAR) 2019

doi:	10.1007/s10067-019-04654-7

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC2109250151

Internformat


LEADER	01000caa a22002652 4500
001	OLC2109250151
003	DE-627
005	20230504120516.0
007	cr uuu---uuuuu
008	230502s2019 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s10067-019-04654-7 \|2 doi
035			\|a (DE-627)OLC2109250151
035			\|a (DE-He213)s10067-019-04654-7-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
082	0	4	\|a 610 \|q VZ
084			\|a 44.00$jMedizin: Allgemeines \|2 bkl
084			\|a 44.83$jRheumatologie$jOrthopädie \|2 bkl
100	1		\|a Yilmaz-Oner, Sibel \|e verfasserin \|0 (orcid)0000-0003-1843-9698 \|4 aut
245	1	0	\|a Predictors and the optimal duration of sustained remission in rheumatoid arthritis
264		1	\|c 2019
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © International League of Associations for Rheumatology (ILAR) 2019
520			\|a Objective To determine predictors and optimal duration of sustained remission (SR) in patients with rheumatoid arthritis (RA). Methods A total of 428 consecutive patients with RA visiting our clinic routinely between 2012 and 2013 were evaluated. Seventy seven of these patients in DAS28 remission were enrolled and followed up for 62.2 ± 9.9 months. Patients in remission ≥ 6 months (SR) and shorter (non: N-SR) were compared in terms of demographic-clinical data and the psychosocial factors. At enrollment, 1st and 5th years, patients in DAS28, SDAI, and Boolean remission were determined. Results Sixty three patients were in SR and 14 in N-SR. Lower baseline DAS28 and HAQ scores, anti-CCP were positive predictors of SR. Although the presence of anxiety, depression, fibromyalgia, and fatigue were lower in the SR group, there was no significance. Patients in DAS28 remission (100%) at baseline reduced to 64% at 1st and 42.6% at 5th years. Patients satisfying SDAI and Boolean remission at these three visits were 49%, 44%, and 32.4% vs 41%, 28%, and 20.6%, respectively. If the duration of remission is defined as 6 months, the remission rates of SDAI at inclusion and fifth years’ visits were similar but Boolean remission rates differed significantly and if it is accepted as ≥ 12 months, both the SDAI and Boolean remission rates were not different. Conclusion Low DAS28 and HAQ scores at baseline, anti-CCP were positive predictors of SR. Instead of 6 months, remission duration for ≥ 12 months would probably help us to predict SR independently from the chosen criteria; Boolean or SDAI.
650		4	\|a ACR/EULAR definition of remission
650		4	\|a Disease activity score
650		4	\|a Predictors
650		4	\|a Rheumatoid arthritis
650		4	\|a SDAI
650		4	\|a Sustained remission
700	1		\|a Gazel, Ummugulsum \|4 aut
700	1		\|a Can, Meryem \|4 aut
700	1		\|a Atagunduz, Pamir \|4 aut
700	1		\|a Direskeneli, Haner \|4 aut
700	1		\|a Inanc, Nevsun \|4 aut
773	0	8	\|i Enthalten in \|t Clinical rheumatology \|d Springer London, 1982 \|g 38(2019), 11 vom: 03. Juli, Seite 3033-3039 \|h Online-Ressource \|w (DE-627)27159909X \|w (DE-600)1480901-1 \|w (DE-576)088704351 \|x 1434-9949 \|7 nnns
773	1	8	\|g volume:38 \|g year:2019 \|g number:11 \|g day:03 \|g month:07 \|g pages:3033-3039
856	4	0	\|u https://dx.doi.org/10.1007/s10067-019-04654-7 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_267
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_711
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2070
912			\|a GBV_ILN_2086
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2116
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	b	k	\|a 44.00$jMedizin: Allgemeines \|q VZ \|0 106409646 \|0 (DE-625)106409646
936	b	k	\|a 44.83$jRheumatologie$jOrthopädie \|q VZ \|0 106409425 \|0 (DE-625)106409425
951			\|a AR
952			\|d 38 \|j 2019 \|e 11 \|b 03 \|c 07 \|h 3033-3039

Predictors and the optimal duration of sustained remission in rheumatoid arthritis

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände